Conferences are invigorating and a great way to share and connect with everyone in the field. This year’s the 2022 European Society of Medical Oncology (ESMO) meeting took place in beautiful Paris, France from September 9th through the 13th. MEDSIR was happy to share two of our trials, PECATI and REVERT, with the medical community and network with all the oncology professionals.
Our team was happy to be back in person!
The MEDSIR team was busy sharing our company model with as many investigators and companies as we could at the conference. We were also able to discuss ongoing proposals and receive some great feedback. Stay tuned for some exciting things coming!
Two of our trials were presented at #ESMO22
Dr. Elena López presented our REVERT trial in the poster session. Dr. López shared some of the results from this trial that is exploring whether eribulin can increase hormonal sensitivity in aromatase inhibitor-pretreated luminal metastatic breast cancer patients. This multicenter, non-comparative, phase 2 trial randomized metastatic breast cancer patients 1:1 to receive either eribulin only or erbulin plus aromatase inhibitors. 22 pts from 7 centers in Spain were enrolled, with a median age was 63.0 years, 95.5% had visceral disease and 36.4% presented ≥3 metastatic sites. On March 31, 2021 the trial was terminated with 8 patients still on treatment. ORR was achieved in 4 of the 15 patients who received Eribulin +Aromatase Inhibitors and 2 of 7 patients receiving Erbulin only. There was a median progression free survival of 6.3 months with Eribulin with Aromatase Inhibitors and 6 months with Eribulin alone. The combination of eribulin plus aromatase inhibitors does not seem to have any benefit but the combination does warrant further investigation for patients with ET-resistant, HR[+]/HER2[-] metastatic breast cancer, after progression toCDK4/6 inhibitors. Click here to download the poster.
In addition to our breast cancer trials we shared the trial design for our rare thymic tumor study, PECATI, presented in the poster sessions by Dr. Jordi Remon. This multicenter, open-label, single-arm, phase 2 trial aims to assess the safety and efficacy of levatinib plus pembrolizumab in pretreated advanced b3-thymoma and thymic carcinoma. The trial is taking place in 6 sites across Spain, France, and Italy, and aims to enroll 43 patients. Patients must be aged ≥ 18 years, have an ECOG performance status of 0–1,with advanced B3-T and TC and measurable lesions by RECIST v.1.1 criteria that progressed following at least one platinum-based chemotherapy, regardless of PD-L1 status. Treatment with previous immunotherapy or sunitinib is not allowed. The primary endpoint is 5-month progression-free survival rate, with secondary endpoints including objective response rate, disease control rate, duration of response, overall survival; and safety and toxicity profile as per NCI-CTCAE v.5.0. Exploratory endpoints include PD-L1 expression, blood tumor mutational burden, immune-related gene signatures, and genomic profiles at baseline and at the time of disease progression. Click here to download the poster.
Dr. Cortés presenting and chairing some talks
One of the co-founders of MEDSIR, Dr. Javier Cortés, was once again very present at this conference.
On Friday 9th, he led the industry Satellite Symposium "SERDS at the inflection point in pretreated ER+/HER2- Breast Cancer".
On Sunday 11th, he shared a Symposium with Maria di Bartolomeo, Nicolas Girard and Shanu Modi on "The current and emerging role of ADCs in cancer therapy".
And Monday 12th was very busy since he was present at the “Targeting HER2 in advanced breast cancer: Successes and perspectives” colloquium and the “Oligometastatic disease and oligoprogression in breast cancer” multidisciplinary session.
The importance of Patient Advocacy Sessions at the congress
Under the theme “I am FINE: Frustrated * Isolated * Neglected * Emotional”, we had the pleasure to be present in this round table and talks from different perspectives: the caregiver, nurse, oncologist and patient advocate. Here are some rescued quotes:
Natacha Bolaños (patient advocate): Fatigue is the leading physical issue affecting the well-being of patients with lymphoma, and it persists long after treatment is completed. Patients are not being educated about fatigue and fatigue management, and the majority feel frustrated because they don’t feel “strong enough”. Let’s help empowering them.
Kate Washington (caregiver): We are neglected, isolated and frustrated because of financial strain (high spending on care cost), intense demands for the caregiver (32h/week for cancer caregiving) and there’s no or very little preparation for care role. With all this pressure, there’s no wonder we’re emotional, exhausted.
Fatima Cardoso (oncologist): Often patients will not tell their oncologist how they really feel. They will be more truthful with the nurse or the psychologist. Remember to ask about the patient not just about the disease or the treatment. It’s also a lot for the oncologist to bear with everything and the burnout is REAL. Seek help. Speak about it. Don’t try to solve it alone.
Lena Sharp (nurse): Suddenly nurses in the whole world became important with the coronavirus. Lena shares “I am suddenly not ‘just a nurse’. I am now a front-line worker and a supposed healt-care hero. Were we not life-saving heroes before the virus?”.The figure of the nurse is key in the cycle of cancer treatment.
MEDSIR Happy Hour was a success!
For the first time since the pandemic, we’ve organized a little event with our dear colleagues, friends and clients and it turned out really well. It was great to see each other again, talk, drink and have some fun.
We love live tweeting at conferences
With so many great presentations and results shared during the conference, MEDSIR worked hard to make sure you don’t miss anything. Head over to our twitter page to see some of our highlights from #ESMO22 and share some of your favorites! We’ve also been selected as one of the Top Twitter accounts for the Tweet compilation of ESMO Congress!
See you next year, #ESMO! Contact us for any extra information requires, we’ll be happy to assist.